PROLIA (denosumab)


Drug overview for PROLIA (denosumab):

Generic name: DENOSUMAB (den-OH-sue-mab)
Drug class: Hypercalcemia Agents
Therapeutic class: Endocrine

Denosumab, a fully human monoclonal antibody that is specific for the receptor activator of nuclear factor kappa-B ligand (RANKL) and acts as a RANKL inhibitor, is a bone resorption inhibitor.

Denosumab (Prolia(R)) is used in the treatment of osteoporosis in postmenopausal women and men at high risk for fracture, in the treatment of glucocorticoid-induced osteoporosis in patients at high risk for fracture, and to increase bone mass in patients at high risk for fracture who are receiving androgen deprivation or aromatase inhibitor therapy. Denosumab (Xgeva(R)) is used to prevent skeletal-related events (SREs) in patients with multiple myeloma or with bone metastases from solid tumors. Denosumab (Xgeva(R)) also is used for the treatment of giant cell tumor of bone and for the treatment of bisphosphonate-refractory hypercalcemia associated with malignant neoplasms; denosumab has been designated an orphan drug by FDA for these uses.
DRUG IMAGES
  • PROLIA 60 MG/ML SYRINGE
    PROLIA 60 MG/ML SYRINGE
The following indications for PROLIA (denosumab) have been approved by the FDA:

Indications:
Glucocorticoid-induced osteoporosis
Loss of bone mineral density (BMD) due to androgen deprivation therapy
Loss of bone mineral density (BMD) due to aromatase inhibitor therapy
Osteoporosis in male patient
Osteoporosis in postmenopausal woman at high risk for fracture


Professional Synonyms:
Androgen ablation induced osteoporosis or osteopenia
Androgen deprivation induced osteoporosis or osteopenia
Androgen suppression induced osteoporosis or osteopenia
Bone loss from androgen ablation
Bone loss from aromatase inhibitor
Glucocorticoid hormone-induced osteoporosis
Glucocorticoid induced osteoporosis
Glycocorticoid-induced osteoporosis
Loss of BMD due to aromatase inhibitor therapy
Osteoporosis in men
Osteoporosis or osteopenia due to ADT
Osteoporosis or osteopenia due to androgen ablation therapy
Osteoporosis or osteopenia due to aromatase inhibitor therapy
Postmenopausal osteoporosis in woman with high fracture risk
Postmenopausal osteoporosis with high fracture risk